Research & Development
Chugai's Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission
15 March 2019 - - Swiss healthcare company Roche (SIX: RO) (OTCQX: RHHBY) has received the decision from the European Commission confirming that Hemlibra (emicizumab), a hemophilia A treatment originated by Japanese drugmaker Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), has EU marketing authorisation for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A (congenital factor VIII deficiency, FVIII


Related Headlines